Efficacy and safety of methotrexate in the management of inflammatory bowel disease
A systematic review and meta-analysis of randomized, controlled trials
Nielsen, Ole Haagen; Steenholdt, Casper; Juhl, Carsten Bogh; Rogler, Gerhard

Published in:
EClinicalMedicine

DOI:
10.1016/j.eclinm.2020.100271

Publication date:
2020

Document version
Final published version

Document license
CC BY-NC-ND

Citation for published version (APA):
Nielsen, O. H., Steenholdt, C., Juhl, C. B., & Rogler, G. (2020). Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine, 20, [100271]. https://doi.org/10.1016/j.eclinm.2020.100271

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 19. Apr. 2021
Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials

Ole Haagen Nielsen\textsuperscript{a,}\textsuperscript{*}, Casper Steenholdt\textsuperscript{a}, Carsten Bogh Juhl\textsuperscript{b,c}, Gerhard Rogler\textsuperscript{d}

\textsuperscript{a} Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{b} Research Unit for Musculoskeletal Function and Physiotherapy, University of Southern Denmark, Odense, Denmark
\textsuperscript{c} Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{d} Department of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland

A R T I C L E   I N F O

Article History:
Received 20 August 2019
Revised 16 January 2020
Accepted 16 January 2020
Available online xxx

Keywords:
Crohn’s disease
Inflammatory bowel disease
Methotrexate
Therapy
Ulcerative colitis

A B S T R A C T

Background: The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear.

Methods: We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD until January 2020 in accordance with PROSPERO protocol (#CRD42018115047). Relative risk (RR) of maintenance of remission, induction of remission, endoscopic disease activity, and adverse events were combined in a meta-analysis.

Findings: MTX monotherapy was not superior to placebo for induction of clinical remission in Crohn’s disease (CD). However, MTX was superior to placebo in maintaining clinical remission of CD. Concomitant therapy with MTX and the TNF inhibitor infliximab (IFX) was not superior to IFX monotherapy in CD. In ulcerative colitis (UC), MTX monotherapy was not superior to placebo neither for induction of clinical remission, nor for maintenance of clinical remission. MTX did not result in superior endoscopic outcomes during induction or maintenance therapy compared with placebo. Regarding adverse events (AEs), our meta-analysis on CD studies showed a significantly higher risk of AEs when comparing MTX versus placebo in studies investigating induction of remission, but not in maintenance of remission. In UC, no such differences in AEs between MTX or placebo were observed.

Interpretation: Current data support the efficacy of parenteral MTX monotherapy for maintenance of clinical remission in CD. MTX is not confirmed to be effective for treatment of UC or for induction of remission in CD. No evidence supports concomitant MTX to improve efficacy of IFX (no other biologics investigated).

© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Despite the introduction of a wide range of novel therapeutic agents for the management of inflammatory bowel disease (IBD), including biologics (e.g., tumor necrosis factor [TNF] inhibitors, cell-migration inhibitors, and anti-interleukins)\textsuperscript{1,2} and small molecules (e.g., JAK inhibitors),\textsuperscript{3} conventional immunomodulators in the form of thiopurines and methotrexate (MTX), along with glucocorticoids, constitute the basic therapeutic armamentarium. European and American guidelines recommend MTX for active Crohn’s disease (CD) as adjunctive therapy or as a steroid-sparing agent to maintain remission [4,5]. MTX is an inexpensive, well-characterized analogue of folic acid and aminopterin that targets the enzyme thymidylate synthetase and dihydrofolate reductase [6]. At high doses (i.e., \( \geq 500 \text{ mg/m}^2 \)), MTX was originally introduced as a chemotherapeutic agent in the 1940s. Later, lower doses of MTX was discovered to have anti-inflammatory properties and consequently was introduced for a wide range of chronic inflammatory conditions [7].

For decades, MTX has been used in the management of IBD, characteristically as a second-line immunomodulator and steroid-sparing agent in patients intolerant to thiopurines or in whom thiopurine treatment has failed [8,9]. However, current recommendations for the use of MTX in CD build on data from nearly 500 patients included in randomized, controlled trials (RCTs) compared with considerably larger cohorts documenting the effects of the thiopurine family of immunomodulators. In ulcerative colitis (UC), data have been

Please cite this article as: O.H. Nielsen et al., Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials, EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100271
Research in context

Evidence before this study

For long, the role of methotrexate (MTX) to treat flares or to maintain remission in ulcerative colitis (UC) has been uncertain as well as if MTX as concomitant therapy to biologics is associated with greater benefits than placebo or alternative therapeutic agents. Therefore, we searched MEDLINE via PubMed, EMBASE via Ovid, and the Cochrane Central Register of Controlled Trials (CENTRAL), all from inception until January 1, 2020 for randomized, controlled trials evaluating the effectiveness of MTX for inflammatory bowel disease (IBD).

Added value of this study

To our knowledge, this is the first comprehensive meta-analysis to evaluate the efficacy of MTX in IBD in a single paper. The meta-analysis of 10 RCTs with 767 participants showed that parenteral MTX is efficacious for maintenance of remission in Crohn’s disease (CD). However, MTX for induction of remission is not effective for CD, and far more potent treatment options are available for treatment of disease flares. In UC, MTX should no longer be considered as a therapeutic option neither for induction or maintenance of remission. MTX as concomitant medication with TNF inhibitors has only been tested with infliximab (IFX) and in CD, and data does not support superiority of MTX-IFX combination therapy over IFX monotherapy.

Implications of all the available evidence

Based on the latest evidence, the use of parenteral MTX monotherapy in the management of patients with IBD should be carefully considered and restricted to situations where there is reliable evidence of benefit, that is in CD as alternative maintenance therapy to thiopurines.

2. Methods

This systematic review and meta-analysis were performed in accordance with the guidelines from Cochrane and reported following the PRISMA guidelines, and the protocol was registered at the PROSPERO database (Reg. No. CRD42018115047) before initiation of the literature search (eAppendix 1).

2.1. Inclusion and exclusion criteria

Studies were eligible for the systematic review if they included (at least) one treatment group in which MTX was administered for IBD compared with a non-exposed control group or studies where MTX was administered as add-on treatment (e.g., MTX was given in intervention groups in addition to the control treatment). Studies in children and the non-English-language literature were excluded. Secondary publications were checked for additional data before exclusion.

2.2. Search strategy and selection criteria

The following bibliographic databases were searched without restriction on language and publication year: MEDLINE via PubMed, EMBASE via Ovid, and the Cochrane Central Register of Controlled Trials (CENTRAL), all from inception until January 1, 2020. Furthermore, the reference lists of the included studies and systematic reviews from the last five years on MTX therapy for the management of IBD were scrutinized for any further studies of relevance.

The following search strategy was performed in MEDLINE and adjusted to the respective databases: (“Inflammatory bowel diseases” [MeSH] OR Crohn” [TIAB] OR ulcerative colitis” [TIAB] OR IBD [TIAB] OR Inflammatory bowel disease” [TIAB] OR proctocolitis” [TIAB] OR proctosigmoiditis” [TIAB] OR rectocolitis” [TIAB] OR rectosigmoiditis” [TIAB] OR proctitis” [TIAB] AND (“methotrexate” [MeSH] OR methotrexate” [TIAB]) AND (randomized controlled trial [Publication Type] OR controlled clinical trial [Publication Type] OR randomized [TIAB] OR placebo [TIAB] OR drug therapy [Subheading] OR randomly [TIAB] OR trial [TIAB] OR groups [TIAB]).

2.3. Data management

A customized data-extraction form was developed for each of the outcomes (eAppendix 2). Extraction of the following data was considered mandatory: authors of the study, year of publication, design of trial, intervention characteristics, location of the trial (in the case of multicenter studies, primary investigator affiliation), number of patients allocated (to the MTX versus control groups, respectively), average patient age, average disease activity score and score applied, endoscopy score and scoring system applied, number of females within the intention-to-treat population, and duration of the study (presented in weeks).

2.3.1. Primary outcome

Efficacy of MTX was accessed based on established disease activity scores used in IBD. For CD, the Crohn’s disease activity index (CDAI) score [14] (150 or below is defined as remission; response ≥70 [Response-70] or response ≥100 [Response-100]) followed by the Harvey and Bradshaw index (HBI) score [15] (remission 0–4, mild 5–7, moderate 8–16, and severe ≥17 [response ≥3 reduction]). For UC, the Mayo score [16] (maximum of 12 points; remission ≤2 [with no item >1], mild 3–5, moderate 6–9, and severe ≥10; response ≥3) or partial score (i.e., without endoscopy [maximum of 9 points]; remission 0–1, mild 2–4, moderate 5–6, and severe 7–9; response ≥2), followed by the simple clinical colitis activity index (SCCAI) [17] (maximum of 15 points including extracolonic manifestations [1 point per manifestation]; remission ≤3, mild 4–6, moderate 7–9, and severe ≥10; response ≥4).

2.3.2. Secondary outcomes

Endoscopic disease activity scores for mucosal healing, defined as an absolute subscore for endoscopy of no more than 1 for the Mayo score [16] (UC); or Crohn’s disease endoscopic index of severity (CDEIS) [18], followed by the simple endoscopic score for Crohn’s disease (SES-CD) [19] (both CD scores ≥2).

Discontinuation of MTX treatment because of side effects was analyzed and presented as the relative risk (RR). A relative risk larger than 1 indicates a larger risk of withdrawal in the MTX group versus the control group.

Please cite this article as: O.H. Nielsen et al., Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials, EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100271
2.4. Study selection and bias assessment

Two members of the study team (OHN and CS) independently accessed titles and abstracts for study eligibility, performed data extraction and assessed risk of bias. The full text was obtained if studies were judged eligible by at least one reviewer. The same two reviewers independently judged eligibility of the retrieved full-text studies. Consensus on inclusion was reached by discussion, including CB and GR. Risk of bias in included studies was evaluated using the Cochrane risk of bias tool assessing whether each of the following domains were adequate (i.e., low risk of bias), unclear, or inadequate: sequence generation, concealment of allocation, blinding, incomplete outcome data addressed, selective outcome reporting.

2.5. Evidence synthesis

A meta-analysis was applied using the restricted maximum likelihood (REML) method as other methods tend to overestimate the precision of the estimate. Relative risk (RR) and 95% confidence interval (CI) were estimated on remission, relapse, endoscopic disease activity, and adverse events (AEs) in the MTX group versus the placebo (control) group.

The meta-analysis was stratified on oral or parenteral (very low i.e. ≤ 12.5 mg/week) or low (i.e., 12.5 - 25 mg/week) dosages of MTX applied, if possible. Heterogeneity was examined as the between-study variation and calculated as the I²-statistic measuring the proportion of variation (i.e., inconsistency) in the combined estimates owing to between-study variance. An I²-value of 0% indicates no inconsistency between the results of individual trials, and an I²-value of 100% indicates maximal inconsistency [20]. For outcome measures for which a meta-analysis was not possible, the results of the individual studies was presented.

2.6. Role of the funding source

This systematic review and meta-analysis was not funded.

3. Results

3.1. Included studies into the systematic review

The literature search identified 6,018 papers, of which 10 RCTs were included in the quantitative evaluation (Table 1, Fig. 1). Overall the study quality was high even though the description of the method, especially the sequence generation and the allocation concealment in the older studies was inadequate, and therefore assessed as being unclear (eTable 1). Six studies, including 479 participants, evaluated the effect in CD (two investigated the effect on induction of remission [21,22], one investigated the effect on maintaining clinical remission [23], and three investigated both outcomes) [24–26]. Further, four trials compared the effect of MTX versus placebo [21–23,25], and two examined the effect of concomitant MTX with the TNF inhibitor infliximab (IFX) versus IFX alone [24,26]. Concerning UC, four studies, including 288 participants, were identified. One study investigated induction of remission [12], two investigated maintenance of clinical remission [13,27], and one studied both outcomes [28].

3.2. Meta-analysis of MTX in Crohn’s disease

Our meta-analysis of the RCTs, presented in Fig. 2 and Table 1, showed no significant effect of MTX monotherapy in the management of CD in three RCTs investigating induction of clinical remission (primary endpoints) [21,22,25] (RR = 1.44; 95% CI 0.71–2.94; I² = 55%). However, when investigating maintenance of clinical remission a significant effect in two RCTs was found (RR = 1.50; 95% CI 1.08–2.07; I² = 0%) [23,25]. Nevertheless, none of the published RCTs in CD assessed endoscopic scores as secondary endpoint. No effect was observed in studies investigating the additional effect of concomitant MTX with IFX versus IFX alone on either induction of clinical remission or maintenance of clinical remission or when assessing mucosal healing by endoscopy [24,26] (Fig. 2). Moreover, the effect of MTX on induction or maintenance of endoscopic healing had not been assessed.

3.3. Meta-analysis of MTX in ulcerative colitis

In UC, the meta-analysis of the primary endpoints showed no significant effect of MTX monotherapy in data derived from two studies investigating induction of clinical remission [12,28] (RR = 1.19; 95% CI 0.72–1.96; I² = 33%; Fig. 2), and there was no effect in the three studies investigating maintenance of clinical remission [13,27,28] (RR = 1.06; 95% CI 0.79–1.43; I² = 32%; Fig. 2). Regarding the secondary endpoints, endoscopic disease activity, MTX for induction (RR = 1.37; 95% CI 0.77–2.46) or maintenance (RR = 0.79; 95% CI 0.43–1.46) of steroid-free endoscopic remission was not superior to placebo. [12,13] Nevertheless, MTX combination therapy with biologics has not yet been investigated in UC.

3.4. Meta-analysis on adverse events of MTX in inflammatory bowel disease

Regarding AEs, our meta-analysis on CD studies showed a significantly higher risk of AEs (defined as MTX withdrawal because of AEs) in three studies investigating induction of remission (RR = 6.40; 95% CI 1.52–27.03; I² = 0%) [21,22,25], but no statistical differences in two studies investigating maintenance of clinical remission (RR = 2.95; 95% CI 0.31–28.19; I² = 0%) [23,25] when comparing the risk of AEs in the MTX group versus placebo (Fig. 3). Further, no differences were observed in two studies investigating the additional effect of concomitant MTX with IFX versus IFX alone [24,26] (Fig. 3). In studies investigating UC, the meta-analysis showed no differences in the risk of AEs in two studies investigating induction of remission (RR = 0.74; 95% CI 0.24–2.26; I² = 30%) [12,28] or in three studies investigating maintenance of remission (RR = 2.91; 95% CI 0.68–12.42; I² = 0%) [13,27,28] when comparing the MTX group with the control group.

There was no difference in severe adverse events (SAEs, i.e., leading to hospitalization) between MTX and placebo as shown in eFig. 1. However, SAEs were only reported in 6 studies (three out of six studies reported SAEs in CD, and three out of four in UC). Due to the low number of reported SAEs, no significant results were found in any of the analyzed subgroups, and the 95% CI were accordingly broad (efig. 1).

4. Discussion

This is the first systematic review and meta-analysis of the combined efficacy of MTX for induction of remission and maintenance of remission in both CD and UC, respectively, based on the latest RCTs. In the late 1980s, the first promising pilot studies were published on MTX monotherapy for IBD indicating a steroid-sparing effect and an ability to induce and maintain clinical remission or even mucosal healing in patients with either steroid-refractory or steroid-dependent disease [29,30]. Over the years, several uncontrolled observational studies [31–40], along with minor RCTs have indicated a benefit of MTX in particular among patients with CD failing thiopurines, but only three state-of-the-art RCTs have supported its clinical efficacy in CD [22–24].

As concerns dosage used in the 10 RCTs included in the quantitative evaluation, in CD two of the older studies (published before 2000) an oral administration was used [21,25], whereas all studies (both before and after year of 2000) from Feagan et al. [22–24] used parenteral administration. The dose of MTX ranged from 10 to 25 mg/week with no clear tendency to have changed over time.

Please cite this article as: O.H. Nielsen et al., Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials, EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100271
| Reference and year | MTX dose | Disease | Objective | Severity | No. of patients | Intervention | Duration | Comedication | Outcome |
|--------------------|----------|---------|-----------|----------|----------------|-------------|----------|--------------|---------|
| Feagan 1995 [22]   | 25 mg/wk parenteral | CD      | Induction of remission | Active CD (CDAI > 150) for a minimum of 3 months despite a minimum of 12.5 mg prednisolone | 141 | MTX (n = 94) or placebo (n = 47) | 16 weeks | Steroid to be tapered, mesalamine, steroid enemas, antibiotics (perianal disease) | CDAI = 150 without prednisolone at week 16; MTX superior to placebo (p = 0.025) |
| Arora 1999 [21]    | 15 – 22.5 mg/wk orally | CD      | Induction of remission | Steroid-dependent CD | 33 | MTX (n = 15) or placebo (n = 18) | 12 months | Prednisolone ≥ 10 mg/day | MTX not superior to placebo for induction of remission (p > 0.05) |
| Oren 1997 [25]     | 12.5 mg/wk orally | CD      | Induction and maintenance of remission | Steroid-dependent CD | 84 | MTX (n = 26) or 6-MP (n = 32) or placebo (n = 26) | 9 months | Steroids and mesalamine | The proportions of patients entering first remission (HBI < 3) or experiencing a relapse (HBI ≥ 3) were without statistically significant differences in the three treatment arms |
| Feagan 2014 [24]   | 10 – 25 mg/wk parenteral | CD      | Induction and maintenance of remission (combination of MTX with IFX versus IFX alone) | Active CD initiated on prednisolone induction therapy | 126 | MTX + IFX (n = 63) or IFX + placebo (n = 63) | 50 weeks | IFX; prednisolone to be tapered no later than week 14 | Time to treatment failure (i.e., failure of CDAI < 150 at week 14 or failure to maintain this remission through week 50); MTX was not superior to concomitant treatment with placebo (p = 0.63) |
| Feagan 2000 [23]   | 15 mg/wk parenteral | CD      | Maintenance of remission | CDAI ≤ 150 at inclusion after previous MTX induction therapy | 76 | MTX (n = 40) or placebo (n = 36) | 40 weeks | Hydrocortisone ointment for perianal disease | Increase in CDAI of more than 100 points or use of rescue medication (steroid/antimetabolite) MTX superior to placebo (p = 0.04) |
| Schrürder 2006 [26] | 20 mg/wk parenteral for first 5 weeks then orally | CD      | Combination with IFX for induction of remission and maintenance | Active CD resistant or intolerant to thiopurines | 19 | MTX + IFX (n = 11) or IFX (n = 8) | 48 weeks | 5-ASA at doses of 4 g or more, prednisolone 40 mg/day or less (table 4 weeks before study entry) | CDAI = 150; time to achieve clinical and the corticosteroid tapering effect of treatment; MTX + IFX not superior to IFX at week 48 (p = 0.63) |
| Oren 1996 [28]     | 12.5 mg/wk orally | UC      | Induction and maintenance of remission | Mayo score ≥ 7 | 67 | MTX (n = 30) or placebo (n = 37) | 9 months | Mesalamine and/or steroids | Proportion entering remission/maintenance of remission, no difference (p > 0.73) |
| Carbonnel 2016 [12] | 25 mg/wk parenteral | UC      | Induction of remission | Mayo score 0–12 but steroid dependent | 111 | MTX (n = 60) or placebo (n = 51) | 24 weeks | Steroid to be tapered | Mayo score ≤ 2 at week 16 without steroid; no difference (p = 0.15) |
| Onuk 1996 [27]     | 15 mg/wk orally | UC      | Maintenance of remission | N/A | 26 | MTX & 5-ASA (n = 14) or MTX (n = 12) | 12 months | Sulfasalazine | Symptoms, sigmoidoscopic and histologic activity; no significant difference (p-value not stated) |
| Herfarth 2018 [13] | 25 mg/wk parenteral | UC      | Maintenance of remission | Active UC nonresponding to other therapies treated with MTX open label for 16 weeks | 84 | (Only responders to 16-week induction) to placebo (n = 40) or MTX (n = 44) | 32 weeks MTX | Mesalamine 2.4 g/day | Relapse-free and combined clinical and endoscopic remission; no difference (p = 0.78) |
In the older studies of UC published before 2000 [27, 28] an oral administration was used in contrast to the newer ones (after 2010) [12,13] which used parenteral administration. Here the dose of MTX, however, changed over time from 12.5–15 mg/week in older studies [27,28] to 25 mg/week in the newer ones, including maintenance of remission [12,13]. This meta-analysis shows that MTX monotherapy is not superior to placebo for induction of clinical (i.e., symptomatic) remission in CD when defined as CDAI < 150 (primary outcome). However, the evidence of no effect of MTX for induction of remission may be low due to heterogeneity and sparse number of studies. Nevertheless, more efficient agents with better safety profiles are available for this indication, and most European and American guidelines do not recommend MTX monotherapy to induce remission in CD [4,41]. Further, parenteral dosages of MTX below 15 mg have not been shown to be effective for maintenance of clinical remission, although the minimal dose of MTX required to maintain remission has not been adequately investigated [41]. Of note, from the meta-analysis it seems that oral administration of MTX have not proven to be effective for maintenance of remission in CD.

Whereas the efficacy of MTX monotherapy has been reasonably well documented in CD, until recently its effectiveness in UC has been equivocal because of several uncontrolled observational studies characterized by small sample sizes, suboptimal oral doses of MTX, poorly designed inclusion criteria, and overall less encouraging findings [10,27,29,30,33,40,43–45]. Despite such failings, MTX therapy has been applied in UC equivalently to CD under the assumption that MTX inhibits dihydrofolate reductase and thus restricts DNA, RNA, and protein synthesis, which is equally effective in both diseases [10,11]. However, because the mechanism of action of MTX dosages of ≤25 mg/week is more uncertain than the crude cytotoxic effect employed for malignancies with substantially higher doses [46], and because the inflammatory mechanisms differ between UC and CD, this extrapolation may have been unsubstantiated.
Until recently, well-established disease activity indices such as the CDAI [14] (and the Mayo score[16] for UC) have been used as “gold standards” to evaluate therapeutic efficacies of drugs, including MTX. Nonetheless, advances in field of endoscopy have expanded our knowledge of the relatively poor agreement between these partially symptom-driven indices and objective endoscopic findings of the degree of intestinal inflammation. Furthermore, these indices have been shown to be prone to intra- and interindividual variability[47–49]. This has lately resulted in a paradigm shift in disease monitoring and trial reporting in IBD because regulatory authorities now require efficacy to be documented by healing of the intestinal mucosa, which is considered a more appropriate clinically and prognostically relevant outcome measure[50,51]. Only limited and low-quality data exist on the ability of MTX monotherapy to induce and maintain endoscopic healing in CD, and these data have thus far not been encouraging[30,52–54]. Thus recommendations for the use of MTX in CD are based on symptomatic

| Author, publication year | Relative Risk with 95% CI | Weight (%) |
|--------------------------|--------------------------|------------|
| **Crohn’s disease - Induction of remission** | | |
| Arora, 1999 | 2.40 [0.51, 11.34] | 8.32 |
| Feagan, 1995 | 2.06 [1.09, 3.89] | 45.84 |
| Oren, 1997 | 0.83 [0.44, 1.58] | 45.84 |
| Heterogeneity: $\chi^2 = 0.21, I^2 = 54.63\%$ | 1.44 [0.71, 2.94] |  |
| Test of $\theta_i = \theta_0$; Q(2) = 4.37, p = 0.11 | | |
| **Crohn’s disease - Induction of remission - add to infliximab** | | |
| Feagan, 2014 | 1.05 [0.79, 1.40] | 82.90 |
| Schröder, 2006 | 1.82 [0.89, 3.73] | 17.10 |
| Heterogeneity: $\chi^2 = 0.07, I^2 = 47.85\%$ | 1.25 [0.76, 2.05] |  |
| Test of $\theta_i = \theta_0$; Q(1) = 1.92, p = 0.17 | | |
| **Crohn’s disease - Maintenance of remission** | | |
| Feagan, 2000 | 1.67 [1.05, 2.67] | 48.27 |
| Oren, 1997 | 1.35 [0.86, 2.12] | 51.73 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 1.50 [1.08, 2.07] |  |
| Test of $\theta_i = \theta_0$; Q(1) = 0.42, p = 0.52 | | |
| **Crohn’s disease - Maintenance - add to infliximab** | | |
| Feagan, 2014 | 0.97 [0.71, 1.32] | 93.71 |
| Schröder, 2006 | 1.82 [0.46, 7.11] | 6.29 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 1.00 [0.74, 1.35] |  |
| Test of $\theta_i = \theta_0$; Q(1) = 0.77, p = 0.38 | | |
| **Ulcerative colitis - Induction of remission** | | |
| Carbonnel, 2016 | 1.62 [0.83, 3.15] | 37.55 |
| Oren, 1996 | 0.96 [0.58, 1.59] | 62.45 |
| Heterogeneity: $\chi^2 = 0.04, I^2 = 32.57\%$ | 1.19 [0.72, 1.96] |  |
| Test of $\theta_i = \theta_0$; Q(1) = 1.48, p = 0.22 | | |
| **Ulcerative colitis - Maintenance of remission** | | |
| Herfarth, 2018 | 0.98 [0.70, 1.37] | 45.98 |
| Onuk, 1996 | 1.32 [0.94, 1.86] | 44.43 |
| Oren, 1996 | 0.64 [0.28, 1.45] | 9.59 |
| Heterogeneity: $\chi^2 = 0.02, I^2 = 31.93\%$ | 1.06 [0.79, 1.43] |  |
| Test of $\theta_i = \theta_0$; Q(2) = 3.21, p = 0.20 | | |

Fig. 2. Use of MTX for the management of CD and UC in the context of disease activity measured on induction and maintenance of remission (primary outcome). CI, confidence interval.
improvements that have not been backed up by objective endoscopic documentation of treatment efficacy.

Efficacy of MTX in UC was recently assessed in two landmark RCTs including endoscopic assessment of mucosal healing: the METEOR trial [12] and the MERIT-UC trial [13]. Although METEOR provided uncertain results regarding the efficacy of MTX as an induction therapy for UC (the primary endpoint as well as nine of 10 secondary endpoints failed), it could be argued that MTX may be used to provide a bridge to another agent for maintenance therapy by reducing the symptoms of active disease and the need for glucocorticoids. Nevertheless, the results of the MERIT-UC study exclude any role of MTX in maintaining remission in UC [13]. Of note, MTX monotherapy did not provide higher rates of endoscopic healing than placebo in UC.

Three underpowered RCTs of which two used an oral dose of MTX, have compared the efficacy of MTX with that of thiopurines in inducing and maintaining remission in patients with CD. Although these studies indicated a comparable efficacy and a similar time to onset of action [25,44,55], thiopurines have generally been preferred over improvements that have not been backed up by objective endoscopic documentation of treatment efficacy.

| Author, publication year | Relative Risk with 95% CI | Weight (%) |
|--------------------------|--------------------------|------------|
| Crohn’s disease - Induction of remission | | |
| Arora, 1999 | 7.46 [0.46, 121.06] | 28.80 |
| Feagan, 1995 | 8.00 [1.09, 58.51] | 47.71 |
| Oren, 1997 | 3.00 [0.13, 70.42] | 23.49 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 6.40 [1.52, 27.03] | |
| Test of $\theta_0 = \theta_1$: $Q(2) = 0.28, p = 0.87$ | | |
| Crohn’s disease - Induction of remission - add to infliximab | | |
| Feagan, 2014 | 0.50 [0.09, 2.63] | 78.49 |
| Schröder, 2006 | 1.00 [0.02, 48.14] | 21.51 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 0.56 [0.12, 2.56] | |
| Test of $\theta_1 = \theta_2$: $Q(1) = 0.10, p = 0.75$ | | |
| Crohn’s disease - Maintenance of remission | | |
| Feagan, 2000 | 2.90 [0.11, 73.27] | 49.02 |
| Oren, 1997 | 3.00 [0.13, 70.42] | 59.98 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 2.95 [0.31, 28.19] | |
| Test of $\theta_1 = \theta_2$: $Q(1) = 0.10, p = 0.99$ | | |
| Crohn’s disease - Maintenance - add to infliximab | | |
| Feagan, 2014 | 0.50 [0.09, 2.63] | 78.49 |
| Schröder, 2006 | 1.00 [0.02, 48.14] | 21.51 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 0.56 [0.12, 2.56] | |
| Test of $\theta_1 = \theta_2$: $Q(1) = 0.10, p = 0.75$ | | |
| Ulcerative colitis - Induction of remission | | |
| Carbonnel, 2016 | 0.57 [0.34, 0.94] | 77.70 |
| Oren, 1996 | 2.47 [0.23, 25.91] | 22.30 |
| Heterogeneity: $\chi^2 = 0.33, I^2 = 30.32\%$ | 0.74 [0.24, 2.26] | |
| Test of $\theta_1 = \theta_2$: $Q(1) = 1.44, p = 0.23$ | | |
| Ulcerative colitis - Maintenance of remission | | |
| Herfarth, 2018 | 4.55 [0.55, 37.28] | 44.93 |
| Onuk, 1996 | 1.00 [0.02, 47.50] | 16.82 |
| Oren, 1996 | 2.47 [0.23, 25.91] | 38.25 |
| Heterogeneity: $\chi^2 = 0.00, I^2 = 0.00\%$ | 2.91 [0.68, 12.42] | |
| Test of $\theta_1 = \theta_2$: $Q(2) = 0.49, p = 0.78$ | | |

**Fig. 3.** Adverse events (AEs) reported when using parenteral MTX for the management of CD and UC. AEs were defined as withdrawal because of AEs. CI, confidence interval.
MTX in the treatment of CD because of their oral administration and better levels of efficacy and safety evidenced.

No data exist on the efficacy of MTX in the postoperative prophylaxis of CD. Preoperative MTX treatment has not been associated with an increased risk of postoperative complications [56]. Apart from case series [26,57–59] and a subgroup analysis of a tiny RCT comparing azathioprine and MTX for induction of fistula closure with similar remission rates observed [55], no data are available on the efficacy of MTX in the treatment of fistulizing CD [60].

Because MTX monotherapy is a cornerstone in the management of rheumatic disorders, including peripheral arthritis and axial arthropathies [61], it can be tried as a primary immunosuppressive agent in patients with CD [62] in order to target both joints and gut [63], although this has not been investigated in RCTs. Likewise, MTX is not being associated with development of malignancies and may be preferred over thiopurines in patients with CD and a previous history of cancer, whereas thiopurines are well-known to increase risks of lymphomas and skin cancers [64,65].

As concerns the efficacy of MTX as concomitant therapy with TNF inhibitors, the COMMIT RCT investigated treatment outcomes of IFX monotherapy (standard induction of 5 mg/kg at weeks 0, 2, and 6 followed by maintenance therapy of 3 mg/kg every 8 weeks; n = 63) versus MTX-IFX combination therapy (25 mg subcutaneously weekly; n = 63) for 50 weeks and with prednisone tapering no later than week 14 [24]. The primary outcome was time to treatment failure, defined as failure to enter prednisone-free remission (CDAI < 150) at week 14 or failure to maintain this remission through week 50. The actuarial rate of treatment failure was 31% in the combined MTX-IFX therapy group, and 30% in the IFX monotherapy group, and secondary endpoints were all negative as well [24]. Thus, at week 52, 56% of patients in combination treatment maintained remission versus 57% in the IFX group [24]. Endoscopic outcomes were not assessed. However, some lower-quality studies have revealed comparable findings [26,66]. Moreover, a recent retrospective observational real-world study concluded that concomitant MTX-IFX therapy for at least three months was inferior to IFX-thiopurine combined therapy [67]. Finally, a retrospective study found that very low-dose MTX (i.e., < 12.5 mg/week) was equally efficient to the typical anti-inflammatory dose of MTX (12.5–25 mg/week) in combination with TNF inhibitors [68]. Although improved efficacy of combination therapy with MTX and biologics remains to be shown, it appears that MTX to some extent can suppress antibodies against IFX and/or increase IFX trough levels in CD [24,69–73]. This phenomenon has been mechanistically related to a possible interaction between MTX and B-cell activating factor (BAFF) [74]. Initiation of combination therapy with MTX in addition to continued treatment with an existing TNF inhibitor has been reported to potentially reverse antidrug antibody–positive status, increase blood levels, and reestablish clinical efficacy [70–72]. However, if used for this indication, potential side effects to both MTX and continued IFX therapy in the presence of anti–IFX antibodies should be balanced against switching to another biologic agent. MTX combination therapy has so far not been examined for UC or for other biologics [6,75,76].

The strength of this meta-analysis is the comprehensive search strategy in relevant databases and that study-selection and risk of bias evaluation was performed by two reviewers independently. Moreover, all RCTs on MTX for IBD in adults published up to 2020 were included, and state-of-the-art statistics (i.e. the restricted maximum likelihood (REML) method) has been applied. However, the review at the same time has some limitations due to the design of the underlying RCTs which were eligible for inclusion. First, the intervention period was not consistent among studies (i.e., a variation from 24 weeks to 1 year was observed). Second, risk of bias from random sequence generation, concealment of allocation, blinding, incomplete outcome addressed, and selective outcome reporting varied among the RCTs included (eTable 1). Third, heterogeneity was seen among the results of the individual trials, and few studies reported on disease activity and side effects defined as withdrawal because of AEs. Fourth, concomitant therapy with IFX was reported in only two of 10 studies (and in CD only), and in an attempt to reduce heterogeneity, subgroup analyses were performed with or without combined therapy for induction of remission or maintenance of clinical remission among patients with CD, resulting in very few studies for each meta-analysis. Publications bias (i.e. small study bias) was not investigated due the small number of studies, however, visual inspection of the forest plot did not indicate that small study bias influenced the interpretation of the results.

The sum of available evidence extracted from this meta-analysis supports the effectiveness of MTX monotherapy (parenterally at 15–25 mg/week) in maintaining clinical remission of CD, whereas its role in induction of clinical remission is doubtful. However, any future studies on CD would benefit from inclusion of mucosal healing in the scoring systems applied. Moreover, for some special indications such as extraintestinal rheumatic manifestations of peripheral arthritis and axial arthropathies or in case of previous malignancies, MTX may be considered as a useful primary maintenance agent of CD, although RCTs in the field are still missing. Finally, more evidence is needed to assess the potential benefit of MTX as a concomitant agent to improve the clinical efficacy and/or pharmacokinetics of different types of biologic agents in IBD.

In conclusion considering the advent of recent high-quality RCTs on patients with UC, including both symptomatic and endoscopic endpoints as recommended by regulatory agencies on both sides of the Atlantic [77,78], data from this systematic review and meta-analysis indicate that it is time to critically readdress the use of MTX in the management of IBD. Thus, when collectively considering this efficacy in adults (i.e., patients of 18 years or older), including lack of data on mucosal healing, safety, and compliance, it is recommended that MTX is being reserved primarily as an option for maintaining clinical remission in CD as an alternative to thiopurines. Even though it cannot be completely ruled out that MTX may have some limited benefits over placebo in the symptomatic treatment of flaring UC, the availability of far more potent and well-documented agents that can induce mucosal healing, including biologics [79] and novel small-molecule drugs [2], renders MTX—based on this systematic review and meta-analysis—not to be confirmed efficient in the treatment of acute flares of IBD. Furthermore, MTX is not confirmed to be effective in the maintenance of clinical or endoscopic remission in UC.

Declaration of Competing Interest

The authors have no competing interests to declare as concerns MTX. In general, OHN, CS, CB] have no conflicts of interest to disclose. Gerhard Rogler has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; received speaker’s honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; and educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.

Author contributions

OHN, CS, CB] and GR had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. This study was not funded. Study concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: OHN. Critical revision of the manuscript for important intellectual content: CS, CB], GR. Statistical analysis: CB]. Study supervision: CS, CB], GR. All authors approved the final version before submission.
Acknowledgements

The authors are grateful to Susanne Knygberg Christensen and Lisa Rohbach for skillful secretarial assistance. This study was not funded.

Funding

No funding was received.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.eclinm.2020.100271.

References

[1] Nielsen OH, Ainsworth MA. Biosimilars for management of Crohn disease. Ann Intern Med 2019;170:129–30.

[2] Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 2017;38:127–42.

[3] Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signalling in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:113–51.

[4] Coskun M, Steenholt C, de Boor NK, Nielsen OH. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet 2016;55:257–74.

[5] Weinstein GD. Methotrexate. Ann Intern Med 1977;86:199–204.

[6] Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 2017;38:127–42.

[7] Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Bailey TJ, Wilkie KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353–6.

[8] Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity of Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724–9.

[9] Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigators. N Engl J Med 1995;332:292–7.

[10] Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther 2001;15:35–44.

[11] Domenne E, Manosa M, Navarro M, et al. Long-term methotrexate for Crohn’s disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008;42:395–8.

[12] Gonzalez-Lama Y, Taxonera C, Lopez-Sanroman A, et al. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol 2012;24:1086–9.
[55] Ardizzone S, Bollani S, Manzoni G, Imbesi V, Colombo E, Bianchi PG. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619–27.

[56] Altali A, Park CJ, Zhu K, et al. Preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1887–95.

[57] Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther 2003;18:1003–8.

[58] Soon SY, Anvari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:921–6.

[59] Scharl M, Rogler G, Biedermann L. Fistulizing Crohn disease. Clin Transl Gastroenterol 2017;8:e106.

[60] Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619–27.

[61] Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1128–34.

[62] Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effective- ness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007;56:1226–31.

[63] Bitoun S, Nocturne G, Ly B, et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis 2018;77:1463–70.

[64] Khan N, Lee H, Trivedi C, et al. Mortality associated with development of squa- mous cell cancer in patients with inflammatory bowel disease receiving treatment with thiopurines. Clin Gastroenterol Hepatol 2019;17:2262–8.

[65] Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679–86.

[66] Sokol H, Selski P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363–8.

[67] Vasudeva A, Raghunath A, Anthony S, et al. Higher mucosal healing with tumor necrosis factor inhibitors in combination with thiopurines compared to metho- trexate in Crohn’s disease. Dig Dis Sci 2019;64:1622–31.

[68] Borren NZ, Luther J, Colizzo FP, Garber JC, Khalili H, Ananthakrishnan AN. Low-dose methotrexate has similar outcomes to high-dose methotrexate in combination with anti-TNF therapy in inflammatory bowel diseases. J Crohns Colitis 2015;9:990–5.

[69] Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019;4:341–53.

[70] Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444–7.

[71] Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019;4:341–53.

[72] Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444–7.

[73] Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1128–34.

[74] Unnar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2017;45:276–82.

[75] Herfarth HH, Kappelman MD, Long MD, Isaac KL. Use of methotrexate in the treatment of inflammatory bowel disease. JAMA 2017;318:1679–86.

[76] Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444–7.

[77] European Medicines Agency (EMA) Guideline on the development of new medicines for inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials, EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100271.